Rate control versus rhythm control for the management of atrial fibrillation: The verdict of the AFFIRM trial

Expert Opinion on Investigational Drugs

Volumn 12, Issue 7, 2003, Pages 1231-1237

  Salam, Amar Mohammad ^a  

^a HAMAD MEDICAL CORPORATION   (Qatar)

Author keywords

Arrhythmia; Atrial fibrillation; Paper evaluation; Rate control; Rhythm control; Trials

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ASCORBIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGITALIS; DIGOXIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DISOPYRAMIDE; DOFETILIDE; ENCAINIDE; FLECAINIDE; IBUTILIDE; MIBEFRADIL; MORACIZINE; PROCAINAMIDE; PROPAFENONE; QUINIDINE; SOTALOL; WARFARIN;

ARTICLE; ARTIFICIAL HEART PACEMAKER; BLOOD DISEASE; BLOOD DYSCRASIA; CARDIOVERSION; CLINICAL PRACTICE; CONGESTIVE HEART FAILURE; DISEASE EXACERBATION; GASTROINTESTINAL SYMPTOM; HEART ATRIUM FIBRILLATION; HEART RATE AND RHYTHM; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERTENSION; HYPOTENSION; LIVER DYSFUNCTION; LUNG TOXICITY; MORBIDITY; MORTALITY; SINUS RHYTHM; SLEEP DISORDER; THROMBOEMBOLISM; THYROID DISEASE; TORSADE DES POINTES; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ARRHYTHMIA; ATRIAL FIBRILLATION; CEREBROVASCULAR ACCIDENT; FEMALE; HEART FAILURE, CONGESTIVE; HEART RATE; HUMANS; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 0037768789     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/eoid.12.7.1231.21763     Document Type: Article

References (18)

1. THE ATRIAL FIBRILLATION FOLLOW-UP INVESTIGATION OF RHYTHM MANAGEMENT (AFFIRM) INVESTIGATORS: A comparison of rate control and rhythm control in patients with atrial fibrillation. N. Engl. J. Med. (2002) 347:1825-1833.
2. WOLF PA, MITCHELL JB, BAKER CS, KANNEL WB, D'AGOSTINO RB: Mortality and hospital costs associated with atrial fibrillation. Cirrulation (1995) 92:I-40.
3. RYDER KM, BENJAMIN EJ: Epidemiology and significance of atrial fibrillation. Am. J. Cardiol. (1999) 84:131R-138R.
4. PACKER DL, BARDY GH, WORLEY SJ et al.: Tachycardia-induced cardiomyopathy: a reversible form of left ventricular dysfunction. Am. J. Cardiol. (1986) 57:563.
5. MANNING WJ, LEEMAN DE, GOTCH PJ, COME PC: Pulsed Doppler evaluation of atrial mechanical function after electrical cardioversion of atrial fibrillation. J. Am. Coll. Cardiol. (1989) 13:617-623.
6. COPLEN SE, ANTMAN EM, BERLIN JA, HEWITT P, CHALMERS TC: Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials. Circulation (1990) 82:1106.
7. EPSTEIN AE, HALLSTROM AP, ROGERS WJ et al.: Mortality following ventricular arrhythmia suppression by encainide, flecainide, and moricizine after myocardial infarction. The original design concept of the Cardiac Arrhythmia Suppression Trial (CAST). JAMA (1993) 270:2451-2455.
8. BRUGADA J, BOERSMA L, KIRCHHOF C, ALLESSIE M: Proarrhythmic effects of flecainide. Experimental evidence for increased susceptibility to reentrant arrhythmias. Circulation (1991) 84:1808-1818.
9. VAN GELDER IC, CRIJNS HJ, TIELEMAN RG et al.: Chronic atrial fibrillation. Success of serial cardioversion therapy and safety of oral anticoagulation. Arch. Intern. Med. (1996) 156:2585-2592.
10. DAVID D, SEGNI ED, KLEIN HO, KAPLINSKY E: Inefficacy of digitalis in the control of heart rate in patients with chronic atrial fibrillation: beneficial effect of an added beta adrenergic blocking agent. Am. J. Cardiol. (1979) 44:1378-1382.
11. HOHNLOSER SH, KUCK KH, LILIENTHAL J: Rhythm or rate control in atrial fibrillation - Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet (2000) 356:1789-1794.
12. LOUIS A, CLELAND JG, CRABBE S et al.: Clinical Trials Update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the Scientific Sessions of the American College of Cardiology, 2001. Eur. J. Heart Fail. (2001) 3:381-387.
13. VAN GELDER IC, HAGENS VE, BOSKER HA et al.: A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N. Engl. J. Med. (2002) 347:1834-1840.
14. MANNING WJ, SILVERMAN DI, KEIGHLEY CS, OETTGEN P, DOUGLAS PS: Transesophageal echocardiographically facilitated early cardioversion from atrial fibrillation using short-term anticoagulation: final results of a prospective 4.5-year study. J. Am. Coll. Cardiol. (1995) 25:1354-1361.
15. AMARENCO P, COHEN A, TZOURIO C et al.: Atherosclerotic disease of the aortic arch and the risk of ischemic stroke. N. Engl. J. Med. (1994) 331:1474-1479.
16. THE STROKE PREVENTION IN ATRIAL FIBRILLATION INVESTIGATORS COMMITTEE ON ECHOCARDIOGRAPHY: Transesophageal echocardiographic correlates of thromboembolism in high-risk patients with nonvalvular atrial fibrillation. Ann. Intern. Med. (1998) 128:639-647.
17. FERRARI E, VIDAL R, CHEVALLIER T, BAUDOUY M: Atherosclerosis of the thoracic aorta and aortic debris as a marker of poor prognosis: benefit of oral anticoagulants. J. Am. Coll. Cardiol. (1999) 33:1317-1322.
18. THE AF-CHF TRIAL INVESTIGATORS: Rationale and design of a study assessing treatment strategies of atrial fibrillation in patients with heart failure: the Atrial Fibrillation and Congestive Heart Failure (AF-CHF) trial. Am. Heart J. (2002) 144:597-607.